Skip to content

A Clinical Trial to Evaluate the Effects of Two Supplements on Cognitive Function, Cognitive Performance, and Mood

A Clinical Trial to Evaluate the Effects of Two Supplements on Cognitive Function, Cognitive Performance, and Mood

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07766564
Enrollment
30
Registered
2026-08-14
Start date
2025-11-09
Completion date
2026-02-06
Last updated
2026-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Function, Cognitive Performance, Mood

Brief summary

This study evaluates the effects of two liquid dietary supplements, BrainJuice Peach Mango (test product one) and BrainJuice ACTIVE Pomegranate Acai (test product two), on cognitive function, cognitive performance, and mood in healthy adults aged 18-57 who report concerns in these areas. The trial is a six-week, single-arm, open-label, virtual study enrolling 30 participants. Participants will consume test product one (2.5 oz once daily) during Weeks 1 and 2, undergo a washout period during Weeks 3 and 4, and then consume test product two (2.5 oz once daily) during Weeks 5 and 6. Cognitive function will be assessed via standardized computerized cognitive assessments at Baseline, Week 2, Week 4, and Week 6, while perceptions of cognitive function, cognitive performance, and mood will be captured through self-reported questionnaires at Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6.

Interventions

DIETARY_SUPPLEMENTBrainJuice Supplement

All participants consume BrainJuice Peach Mango (test product one, 2.5 oz once daily) during Weeks 1 and 2, followed by a washout period during Weeks 3 and 4 with no test product, followed by BrainJuice ACTIVE Pomegranate Acai (test product two, 2.5 oz once daily) during Weeks 5 and 6. There is no comparator or placebo arm.

Sponsors

BrainJuice
Lead SponsorINDUSTRY
Citruslabs
CollaboratorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 57 Years
Healthy volunteers
Yes

Inclusion criteria

* Be male or female * Be aged 18-57 * Anyone experiencing concerns regarding all of the following over the past four weeks: Cognitive Function, Cognitive Performance, and Mood * Anyone who is generally healthy - does not live with any uncontrolled chronic disease * If taking oral over-the-counter supplements or herbal remedies targeted at cognitive function, cognitive performance, or mood, has been consistently taking these for at least 3 months prior to starting the study, and is willing to maintain this routine for the study duration * Anyone who is a regular caffeine consumer without a history of caffeine sensitivity or intolerance * Willing to maintain the same diet and exercise regimen consistently throughout the study duration * Willing to limit caffeine consumption to one additional serving of caffeine outside of the test product i.e. one cup of brewed coffee (\~100 mg), one matcha (\~60 mg), two shots of espresso (\~120 mg), or one cup of caffeinated tea (\~50 mg) * Resides in the United States * Has access to a computer or tablet device

Exclusion criteria

* Anyone with pre-existing chronic conditions, including but not limited to oncological, uncontrolled hypertension (high blood pressure) or hypotension (low blood pressure), heart disease, diabetes and psychiatric disorders * History of neurodegenerative disease (e.g., Alzheimer's, Parkinson's), history of traumatic brain injury (including concussions), stroke, epilepsy, or uncontrolled migraine * History of mood disorders, such as depression, bipolar disorder, or seasonal affective disorder * History of sleep disorders, such as insomnia, narcolepsy, or sleep apnea * Anyone with a job that involves shift work that may be overnight or night hours * Planning on introducing any products or any new forms of prescription medication or supplements that target cognitive function, cognitive performance, or mood, for the study duration * Anyone with any allergies or sensitivities to any of the study product ingredients * Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period) * Anyone unwilling to follow the study protocol * Anyone with a history of substance abuse * Anyone who is currently a smoker or has been a smoker in the past 3 months * Currently partaking in another research study or will be partaking in any other research study at any point during this study's duration

Design outcomes

Primary

MeasureTime frameDescription
Change in Cognitive Assessment Score (Polygons)Baseline, Week 2, Week 4, and Week 6Mean change in Polygons processing test score from Baseline, measured via computerized cognitive assessment
Change in Cognitive Assessment Score (Double Trouble)Baseline, Week 2, Week 4, and Week 6Mean change in Double Trouble selective attention and processing speed test score from Baseline, measured via computerized cognitive assessment
Change in Cognitive Assessment Score (Feature Match)Baseline, Week 2, Week 4, and Week 6Mean change in Feature Match focus and processing test score from Baseline, measured via computerized cognitive assessment
Change in Cognitive Assessment Score (Paired Associates)Baseline, Week 2, Week 4, and Week 6Mean change in Paired Associates memory task score from Baseline, measured via computerized cognitive assessment
Change in Cognitive Assessment Score (Digit Span)Baseline, Week 2, Week 4, and Week 6Mean change in Digit Span short-term memory and attention test score from Baseline, measured via computerized cognitive assessment
Change in Cognitive Assessment Score (Spatial Planning)Baseline, Week 2, Week 4, and Week 6Mean change in Spatial Planning executive function test score from Baseline, measured via computerized cognitive assessment

Secondary

MeasureTime frameDescription
Change in Self-Reported FocusBaseline, Week 1, Week 2, Week 4, Week 5, and Week 6Mean change in perceived focus from Baseline, assessed via self-reported questionnaire
Change in Self-Reported AttentionBaseline, Week 1, Week 2, Week 4, Week 5, and Week 6Mean change in perceived attention from Baseline, assessed via self-reported questionnaire
Change in Self-Reported ConcentrationBaseline, Week 1, Week 2, Week 4, Week 5, and Week 6Mean change in perceived concentration from Baseline, assessed via self-reported questionnaire
Change in Self-Reported ProductivityBaseline, Week 1, Week 2, Week 4, Week 5, and Week 6Mean change in perceived productivity from Baseline, assessed via self-reported questionnaire
Change in Self-Reported AlertnessBaseline, Week 1, Week 2, Week 4, Week 5, and Week 6Mean change in perceived alertness from Baseline, assessed via self-reported questionnaire
Change in Self-Reported Mental ClarityBaseline, Week 1, Week 2, Week 4, Week 5, and Week 6Mean change in perceived mental clarity from Baseline, assessed via self-reported questionnaire
Change in Self-Reported MoodBaseline, Week 1, Week 2, Week 4, Week 5, and Week 6Mean change in perceived mood from Baseline, assessed via self-reported questionnaire
Change in Self-Reported Mental FatigueBaseline, Week 1, Week 2, Week 4, Week 5, and Week 6Mean change in perceived mental fatigue from Baseline, assessed via self-reported questionnaire
Change in Self-Reported MotivationBaseline, Week 1, Week 2, Week 4, Week 5, and Week 6Mean change in perceived motivation from Baseline, assessed via self-reported questionnaire
Change in Self-Reported OrganizationBaseline, Week 1, Week 2, Week 4, Week 5, and Week 6Mean change in perceived organization from Baseline, assessed via self-reported questionnaire

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 15, 2026